SCHEMBL26239676

SCHEMBL26239676

Cc1cnc(NC(C)C)c(C(C)C)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PIP4K2A P48426 1/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
RAB9A P51151 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PDE10A Q9Y233 3/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
LRRK2 Q5S007 1/20 0.33
CCR1 P32246 1/20 0.32
CCR5 P51681 1/20 0.32
CCR8 P51685 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
GRM5 P41594 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27102688 0.82 CCR1 (0.33) LMNACCR1CCR5CCR8NOS3
SCHEMBL19121408 0.80 NOS3 (0.43) LMNAHTTSMN1; SMN2PIP4K2AKDM4E
SCHEMBL26239673 0.79 GABRA1 (0.39) LMNAHTTSMN1; SMN2KDM4ENPC1
SCHEMBL26239679 0.79 JAK2 (0.35) LMNAHTTSMN1; SMN2PDE10AIRAK4
SCHEMBL12411169 0.77 PDE10A (0.43) LMNAHTTSMN1; SMN2PIP4K2AKDM4E
SCHEMBL25884179 0.77 PDE10A (0.43) LMNAHTTSMN1; SMN2PIP4K2AKDM4E
SCHEMBL15426471 0.77 NOS3 (0.41) LMNAHTTSMN1; SMN2PIP4K2AKDM4E
SCHEMBL18371942 0.74 KDM4E (0.40) LMNAHTTKDM4ENPC1TP53
SCHEMBL23792399 0.74 CAMKK2 (0.43) LMNASMN1; SMN2NPC1TP53TSHR
SCHEMBL26240082 0.74 PDE10A (0.36) KDM4EPDE10ALRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-20230134932-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 LMNA 2647/4885HTT 1458/4885SMN1; SMN2 2186/4885
US-20230134932-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 LMNA 2647/4885HTT 1458/4885SMN1; SMN2 2186/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 LMNA 2647/4885HTT 1458/4885SMN1; SMN2 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.